{"filing":{"accession_number":"0001193125-26-288533","cik":"0001613780","ticker":"DBVTF","company_name":"DBV Technologies S.A.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"d108693d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1613780/000119312526288533/d108693d8k.htm"},"events":[{"id":14666,"run_id":13064,"accession_number":"0001193125-26-288533","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"DBV Technologies disclosed a regulatory milestone update regarding its BLA (Biologics License Application) submission for VIASKIN® Peanut Patch in children aged 4-7 years. The company reported productive FDA engagement, confirmation that no additional data was requested, and a revised timeline for BLA submission to Q3 2026. This is a material operational/regulatory event affecting the company's product development trajectory and investor expectations, but does not fit the specific categories of earnings release, M\u0026A activity, impairment, or other defined event types. The disclosure centers on a strategic regulatory milestone rather than a discrete operational restructuring or contract.","company_name":"DBV Technologies S.A.","ticker":"DBVTF","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":12161,"accession_number":"0001193125-26-288533","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"DBV Technologies disclosed a regulatory milestone update regarding its BLA (Biologics License Application) submission for VIASKIN® Peanut Patch in children aged 4-7 years. The company reported productive FDA engagement, confirmation that no additional data was requested, and a revised timeline for BLA submission to Q3 2026. This is a material operational/regulatory event affecting the company's product development trajectory and investor expectations, but does not fit the specific categories of earnings release, M\u0026A activity, impairment, or other defined event types. The disclosure centers on a strategic regulatory milestone rather than a discrete operational restructuring or contract.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:30:03.714126+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12161,"accession_number":"0001193125-26-288533","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"DBV Technologies disclosed a regulatory milestone update regarding its BLA (Biologics License Application) submission for VIASKIN® Peanut Patch in children aged 4-7 years. The company reported productive FDA engagement, confirmation that no additional data was requested, and a revised timeline for BLA submission to Q3 2026. This is a material operational/regulatory event affecting the company's product development trajectory and investor expectations, but does not fit the specific categories of earnings release, M\u0026A activity, impairment, or other defined event types. The disclosure centers on a strategic regulatory milestone rather than a discrete operational restructuring or contract.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:30:03.714126+00:00","company_name":"DBV Technologies S.A.","ticker":"DBVTF","filing_date":"2026-06-29"}]}